Dr. von Haunersches Kinderspital, LMU
- Address
- lock Available on a paid plan
Dr. von Haunersches Kinderspital, LMU - Pediatric Gastroenterology Research
Dr. von Haunersches Kinderspital at Ludwig-Maximilians-Universität (LMU) München is a leading pediatric research center dedicated to advancing treatment options for children with complex gastrointestinal disorders. The center specializes in evaluating novel therapeutic approaches for pediatric inflammatory bowel disease, with particular expertise in managing severe cases that require innovative treatment strategies.
- Pediatric ulcerative colitis treatment optimization
- JAK inhibitor therapy in children with inflammatory bowel disease
- Long-term maintenance therapy for moderate to severe pediatric UC
The center's research program focuses on evaluating the efficacy and safety of tofacitinib and other targeted therapies in achieving and maintaining remission in pediatric patients with moderately to severely active ulcerative colitis. Through rigorous clinical investigation, the team contributes to expanding treatment options for children who may not respond adequately to conventional therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. von Haunersches Kinderspital, LMU
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Tafasitamab in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia: A Phase I/II, Single-Arm, Open-Label, Multicenter Study | Universitaetsklinikum Tuebingen AöR | Phase I | Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tafasitamab | 1 | Unknown | 2023-08-11 | 2023-08-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.